Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound‐guided biopsy: the Victorian Transperineal Biopsy Collaboration experience

Ong, Wee Loon; Weerakoon, Mahesha; Huang, Sean; Paul, Eldho; Lawrentschuk, Nathan; Frydenberg, Mark; Moon, Daniel; Murphy, Declan; Grummet, Jeremy

doi:10.1111/bju.13031

Cited by 50 publications

(29 citation statements)

References 53 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transrectal ultrasound-guided prostate biopsy neglects prostate cancer located in the anterior fibromuscular stroma, whereas the TPUSPB does not. 16 In our study, a significant proportion of positive prostatic cores were found in the anterior fibromuscular stroma among patients in the TPUSPB group. Moreover, some patients with prior negative findings in TRUSPB were diagnosed with prostate cancer in the anterior fibromuscular stroma based on the results of TPUSPB.…”

Section: Discussionsupporting

confidence: 48%

“…First, a consistent number of cores was biopsied in all patients in the TPUSPB group, irrespective of prostate size. To improve the rate of prostate cancer detection, some experts have advocated for the use of different numbers of prostate biopsies, based on prostate size 16 -more biopsies should be taken in patients with larger prostates. Second, TPUSPB required more time than TRUSPB.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy

Chui

Leung

et al. 2019

Hong Kong Med J

View full text Add to dashboard Cite

To compare the clinical outcomes and pathological findings of transperineal ultrasoundguided prostate biopsy (TPUSPB) and transrectal ultrasound-guided prostate biopsy (TRUSPB) in a secondary referral hospital. Methods: This was a retrospective study of 100 TPUSPBs and 100 TRUSPBs performed in our centre. Pre-biopsy patient parameters (eg, patient age, clinical staging, serum prostate-specific antigen [PSA] level, prostate size, and PSA density), as well as pathological results and 30-day complication and readmission rates, were retrieved from the patients' medical records and compared between the two groups.

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy

Chui

Leung

et al. 2019

Hong Kong Med J

View full text Add to dashboard Cite

show abstract

“…Rectal cleansing with povidine‐iodine enemas has shown some benefit but the technique does not negate the need for antibiotic prophylaxis . With limited sustainable options for escalating TRUS biopsy prophylaxis, our institution has been increasingly utilising transperineal prostate biopsy, which we have shown to have a near‐zero sepsis rate , as well as offering a high rate rate of detection of clinically significant prostate cancer . With more limited resources it may be appropriate to reserve transperineal prostate biopsies to those patients at higher risk of harbouring resistant organisms.…”

Section: Discussionmentioning

confidence: 99%

The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy‐related infection over 5 years

et al. 2015

Self Cite

View full text Add to dashboard Cite

Objectives To describe the incidence, morbidity and mortality of men who developed infectious complications requiring hospital admission following TRUS prostate biopsy in Victoria, Australia. Further it aimed to report the financial cost of these admissions. Subjects & Methods The Department of Health's Victorian Admitted Episodes Data Set was used to identify those patients who underwent TRUS biopsy in Victoria who were subsequently readmitted within 7 days to any Victorian hospital with infective complications from July 2007 to June 2012. All Victorian public and private hospitals were included. Patients were excluded if their biopsy was performed during a multi‐day admission. Financial costing data was obtained where available from the Department Of Health and Human Services for readmissions with post‐TRUS infection where available and adjusted to 2012 prices. Institutional ethics committee approval was granted for this study. Results Thirty‐four thousand eight hundred and sixty‐five TRUS biopsies were performed in the 5‐year period. 1276 (3.66%) were readmitted to a Victorian hospital within 7 days. 604 (1.73%) of these were readmitted with a biopsy‐related infection. No significant trend in sepsis rates was seen in 5 years. The median readmission LOS was 4 days. The total burden of readmissions was 3 686 days over 5 years. One patient readmitted with a biopsy related infection died during that episode of care. 20 051 (57.51%) of biopsies resulted in a diagnosis of prostate cancer. Financial costing data was available for 218 (36%) of infectious readmissions with a mean cost per readmission were $7 362 AUD (£4137 or $6844 USD, 95% CI $6219–8505 AUD) or $1 256 AUD per day. Conclusion Infection following TRUS biopsy was associated with a readmission rate for infection of 1 in 57 biopsies, an excess of 3 686 bed days required over 5 years with a cost of $1 256 AUD per day. The rate of infection remained stable for the period examined.

show abstract

“…Thus, various methods permit the results of the mpMRI to guide subsequent prostate biopsy; however, the most efficient is probably the MRI‐TRUS fusion method. The biopsy approach can also be transperineal, which is accepted as safer when possible sepsis‐related complications of the transrectal approach are considered . Aside from how the needle is placed in the prostate, whether perineal or transrectal, MRI plays a major role in identifying the target lesion(s) and guiding the needle path.…”

Section: Mpmri‐transrectal Ultrasound Fusion Biopsiesmentioning

confidence: 99%

Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer

Türkbey

Brown

Sankineni

et al. 2015

CA A Cancer J Clinicians

149

View full text Add to dashboard Cite

Imaging has traditionally played a minor role in the diagnosis and staging of prostate cancer. However, recent controversies generated by the use of prostate-specific antigen (PSA) screening followed by random biopsy have encouraged the development of new imaging methods for prostate cancer. Multiparametric magnetic resonance imaging (mpMRI) has emerged as the imaging method best able to detect clinically significant prostate cancers and to guide biopsies. Here, the authors explain what mpMRI is and how it is used clinically, especially with regard to high-risk populations, and we discuss the impact of mpMRI on treatment decisions for men with prostate cancer. CA Cancer J Clin 2016;66:326-336. © 2015 American Cancer Society.

show abstract

Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound‐guided biopsy: the Victorian Transperineal Biopsy Collaboration experience

Cited by 50 publications

References 53 publications

Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy

Outcomes of transperineal and transrectal ultrasound-guided prostate biopsy

The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy‐related infection over 5 years

Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer

Contact Info

Product

Resources

About